Clinical Trials Logo

Filter by:
NCT ID: NCT01930175 Terminated - Pemphigus Vulgaris Clinical Trials

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

Start date: December 18, 2013
Phase: Phase 2
Study type: Interventional

The study evaluated the efficacy, safety and pharmacokinetics of VAY736 in the treatment of patients with pemphigus vulagaris (PV).

NCT ID: NCT01928979 Completed - Atrial Fibrillation Clinical Trials

Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy

CLOT-AF
Start date: May 2013
Phase: N/A
Study type: Observational

Thrombus outcome data will be collected retrospectively during 2011-2012 as a historical baseline of SoC with oral VKA (Vitamin K Antagonist(s) for the treatment of patients with nonvalvular AF or atrial flutter documented with LA/ LAA thrombi on transesophag-eal echocardiography (TEE). The study is a company-sponsored, global, multi-center, retrospective, non-interventional study. Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012 will be identified through screening and review of medical records and included in the registry. Retrospective patient data will be collected from May 2nd, 2013 to May 2nd, 2014. The observation of each patient will cover the period from the diagnosis of an LA/ LAA thrombus until the end-of-treatment TEE following the 3-12 week SoC anticoagulation (AC) therapy. If no end-of-treatment TEE has been performed during 3-12 weeks of AC therapy, the observational period will end at 12 weeks after diagnosis at the latest. If more than one TEE was performed during treatment, the thrombus outcome will be collected from the last TEE performed within 12 weeks of treatment start.

NCT ID: NCT01928771 Completed - Asthma Clinical Trials

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

Start date: September 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.

NCT ID: NCT01926912 Completed - Schizophrenia Clinical Trials

A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting

HOSPIPalm
Start date: May 2013
Phase: Phase 4
Study type: Observational

The purpose of this study to evaluate safety, tolerability, treatment outcomes, appropriate use and pattern of paliperidone palmitate usage in participants with schizophrenia in the hospital setting.

NCT ID: NCT01926782 Completed - Clinical trials for Hypercholesterolemia

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine if the study drug (alirocumab)administered every 4 weeks, given by injection under the skin is effective and safe compared with placebo in lowering cholesterol, if used alone or added to the participants' current cholesterol-lowering medication.

NCT ID: NCT01925157 Completed - Clinical trials for Rheumatoid Arthritis

A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

Start date: August 2013
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as LY3090106 in healthy participants and in participants with RA who are having an inadequate response to methotrexate (MTX). The study will investigate how the body processes the study drug and how the study drug affects the body. The study will last about 3 months for each participant.

NCT ID: NCT01923181 Completed - Clinical trials for Diabetes Mellitus, Type 2

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Start date: December 2, 2013
Phase: Phase 2
Study type: Interventional

This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.

NCT ID: NCT01923168 Completed - Breast Cancer Clinical Trials

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Start date: March 11, 2014
Phase: Phase 2
Study type: Interventional

The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in patients with Breast cancer.

NCT ID: NCT01922258 Completed - Alzheimer's Disease Clinical Trials

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Start date: September 2013
Phase: Phase 3
Study type: Interventional

To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type

NCT ID: NCT01922089 Completed - Clinical trials for Heart Failure With Reduced Ejection Fraction

Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

TITRATION
Start date: November 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.